Cambridge Open Engage home
What is Cambridge Open Engage?
How to Submit
Browse
About
News [opens in a new tab]

Virtual Screening of Leishmanial Pyridoxal Kinase Enzyme Inhibitors by Repurposed Anti-Trypanosomal Libraries Reveals Two Core Scaffolds

13 October 2020, Version 1
Working Paper
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Leishmania is an intracellular protozoal infection, and it is classified as a neglected disease by the World Health Organization (WHO). Annually more than 2 million newly diagnosed cases were treated with highly toxic drugs. Leishmanial pyridoxal kinase enzyme (LPDxK) is an essential and druggable target. DNDI1103666 is the most promising lead as a potential inhibitor for LPDxK

Keywords

Neglected diseases
Leishmania
virtual screening
LPDxK
Leishmanial pyridoxal kinase inhibitors
repurposing

Supplementary weblinks

Title
Description
Actions
Title
Description
Actions
View

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.

Version History

Oct 13, 2020 Version 1

Metrics

1,870
491
0
Views
Downloads
Citations

License

CC logo
CC
BY logo
BY
NC logo
NC
ND logo
ND
The content is available under CC BY NC ND 4.0 [opens in a new tab]

DOI

10.26434/chemrxiv.13077395.v1
D O I: 10.26434/chemrxiv.13077395.v1 [opens in a new tab]

Author’s competing interest statement

no conflict of interest

Share